All tags FirePlex mrRNA Assays Discovering the C. elegans miRNAome: high-resolution and sensitive miRNA quantitation using the FirePlex® Platform webinar

Firefly multiplex immunoassay and miRNA multiplex assay

Discovering the C. elegans miRNAome: high-resolution and sensitive miRNA quantitation using the FirePlex® Platform webinar

Current microarray-based methods for miRNA expression can not distinguish between targets that are equally expressed in multiple tissues.

Listen in as Dr Swathi Arur, of the MD Anderson Cancer Center, discusses how the FirePlex® miRNA Discovery Panels are designed to sensitively profile individual miRNAs and overcome the limitations seen within current microarray methods.

48:19
48:19
Wistia video thumbnail - Discovering the C. elegans miRNAome: high-resolution and sensitive miRNA quantitation using the FirePlex® Platform

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?

Cancel
message

Webinar topics:

  • Methods to assay miRNA expression
  • Limitations of current assay miRNA expression
  • Using the FirePlex​® platform to profile microRNAs from oocytes and female meiotic cells on dissected germ lines from C. elegans  

Meet our presenter:

    Dr. Swathi Arur obtained her PhD with Prof. M.K. Bhan from the All India Institute of Medical Sciences. She undertook her post-graduate studies with Dr. David Han, at the UCONN Health Science Center, where she spearheaded one of the earliest efforts in deploying state-of-the-art differential proteomics technology (LC-MS/MS coupled with ICAT) to understand how dying cells were cleared by phagocytes. Her studies led to the discovery of the first ‘eat-me’ signal (Annexin I) secreted by the dying apoptotic cell, which enabled its recognition and removal by phagocytes. 

    Subsequently, Dr. Arur received a postdoctoral fellowship from the Washington University school of Medicine in St. Louis to train in the laboratory of Prof. Tim Schedl. During her postdoctoral training, Dr. Arur developed an approach that integrated bioinformatics, proteomics with the power of model-organism genetics to identify substrates of ERK – the terminal kinase of the RAS oncogenic pathway. Her studies discovered more than 30 new ERK targets and unraveled several new themes in RAS-ERK regulation.

    Dr. Arur has run her research lab at the MD Anderson Cancer Center since 2010. She is a Research Scholar of the American Cancer Society, Anna Fuller Foundation, and Andrew Sabin Family Award. Her laboratory is currently funded by the National Institute of Health, Cancer Prevention and Research Institute of Texas and American Cancer Society.

Sign up